Bessemer Group Inc. Raises Stake in Medtronic PLC $MDT

Bessemer Group Inc. grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 86.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,538,029 shares of the medical technology company’s stock after acquiring an additional 1,174,765 shares during the quarter. Bessemer Group Inc. owned 0.20% of Medtronic worth $241,723,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in MDT. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter valued at approximately $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic in the third quarter worth approximately $29,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic in the second quarter worth $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic during the 3rd quarter valued at $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic during the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on MDT. Robert W. Baird set a $103.00 price objective on shares of Medtronic in a research note on Tuesday, December 16th. Jefferies Financial Group restated a “hold” rating and set a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. UBS Group reiterated a “neutral” rating and issued a $104.00 price objective on shares of Medtronic in a research report on Wednesday. Finally, CICC Research began coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating for the company. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $110.67.

Medtronic Stock Down 1.3%

Shares of MDT stock opened at $101.81 on Thursday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The stock has a market cap of $130.52 billion, a P/E ratio of 27.44, a P/E/G ratio of 2.72 and a beta of 0.71. The company has a 50 day simple moving average of $99.48 and a two-hundred day simple moving average of $95.96.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s payout ratio is currently 76.55%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will exercise its option to acquire CathWorks for up to $585 million, adding AI-enabled coronary imaging/diagnostics to its interventional cardiology and cath-lab portfolio — a clear strategic bolt-on that could expand addressable market and recurring software/diagnostic revenues. Medical device maker Medtronic to buy CathWorks in up to $585 million deal Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: New analyst coverage: Citigroup started coverage with a Buy rating and $117 price target (roughly mid-teens upside from current levels), which can support renewed investor demand and higher price targets among peers.
• Positive Sentiment: Recent quarterly results showed an earnings beat and management set FY26 EPS guidance in the $5.62–$5.66 range, signaling durable margins and cash flow that underpin dividend safety and buyback capacity.
• Positive Sentiment: Dividend/quality narrative remains supportive: coverage highlighting Medtronic as a reliable dividend healthcare pick reinforces interest from income-oriented investors. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Company messaging and product launch activity emphasize expansion of heart and diabetes tools, but a recent article notes Medtronic’s valuation is approaching analyst targets — suggesting limited near-term upside unless acceleration in top-line or margin improvement shows up. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Negative Sentiment: Leadership change: Nina Goodheart, President of Structural Heart, is retiring — a near-term governance/operational uncertainty for a key growth business that could weigh on sentiment until succession clarity is provided. Medtronic Structural Heart President Nina Goodheart to retire

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).